RAUL ULLOA VALLADARES: Open Payments
NPI 1922574185 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,238 in 100 payments from 12 companies in 2025. Trend: 2023 $1,950 · 2024 $1,580 · 2025 $2,238
Food & beverage: $2,229Education: $9
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $347 |
| Alkermes, Inc. | 15 | $342 |
| Indivior Inc. | 11 | $336 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $226 |
| E.R. Squibb & Sons, L.L.C. | 10 | $226 |
| Neurocrine BioSciences, Inc. | 7 | $199 |
| Janssen Pharmaceuticals, Inc | 10 | $193 |
| ABBVIE INC. | 6 | $119 |
| Luye Pharma (USA) Ltd. | 5 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $87 |
Products named: SUBLOCADE, UZEDY, CAPLYTA, COBENFY, INGREZZA, INVEGA SUSTENNA, VIVITROL, ARISTADA.
Industry payments across FL — which companies pay providers there.
